Scarica l'app Stockscreener
541.69
1.07%
-5.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$547.55
Aprire:
$547.09
Volume 24 ore:
886.75K
Relative Volume:
0.58
Capitalizzazione di mercato:
$137.30B
Reddito:
$12.34B
Utile/perdita netta:
$4.34B
Rapporto P/E:
32.11
EPS:
16.8685
Flusso di cassa netto:
$3.71B
1 W Prestazione:
-1.16%
1M Prestazione:
+10.46%
6M Prestazione:
+9.03%
1 anno Prestazione:
+38.17%
Intervallo 1D:
$540.08
$549.57
Intervallo di 1 settimana:
$540.08
$555.69
Portata 52W:
$374.17
$555.69
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Aggiornamento | Maxim Group | Hold → Buy |
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-03-10 | Reiterato | Oppenheimer | Outperform |
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? - The Globe and Mail
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? - The Motley Fool
Why Is Vertex Pharmaceuticals (NASDAQ:VRTX) Pipeline Value in Focus? - Kalkine Media
Vise Technologies Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Trillium Asset Management LLC Acquires New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
PCM Encore LLC Invests $1.06 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
B. Metzler seel. Sohn & Co. AG Acquires Shares of 231,381 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of New York Mellon Corp Purchases Shares of 1,672,623 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Reinforces Dominance in Cystic Fibrosis Market as Competitor Falters - SSBCrack
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - AOL.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Enters New Healthcare Focus - Kalkine Media
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Madison Asset Management LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Somerville Kurt F Invests $8.17 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Westport Asset Management Inc. Purchases New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
8,423 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Notis McConarty Edward - MarketBeat
Puzo Michael J Purchases Shares of 15,907 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
11,305 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by NewEdge Wealth LLC - MarketBeat
Knuff & Co LLC Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
DCF Advisers LLC Invests $5.71 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock Price Live, Charts & News - The Economic Times
AssuredPartners Investment Advisors LLC Invests $2.06 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Are Wall Street Analysts Bullish on Vertex Stock? - Barchart.com
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 4.48% on Aug 19: Drivers Behind the Movement - TradingKey
Crinetics (CRNX) projects $1B+ 2030 revenue for Vertex deal - Stock Titan
What Is Putting Vertex Pharmaceuticals (NASDAQ:VRTX) Under the Spotlight? - Kalkine Media
Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 1-Year HighHere's What Happened - MarketBeat
Vertex Pharmaceuticals stock hits all-time high at 546.17 USD - Investing.com
Vertex Pharmaceuticals stock hits all-time high at 546.17 USD By Investing.com - Investing.com South Africa
0000875320-22-000017 | 8-K - Vertex Pharmaceuticals Newsroom
Wealthfront Advisers LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Meeder Advisory Services Inc. Buys Shares of 6,415 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Pallas Capital Advisors LLC Takes $1.09 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Danske Bank A S Takes $78.52 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
27,829 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Danica Pension Livsforsikringsaktieselskab - MarketBeat
Vertex Pharma stock holds at record levels as analysts highlight competitive win - Ad-hoc-news.de
BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600 - Moomoo
Bernstein Names Top Biotech Stock Pick: Vertex Leads After Rival Drug Fails - Investing.com Nigeria
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
UNIVEST FINANCIAL Corp Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Perigon Wealth Management LLC Takes $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Citizens Financial Group Inc. RI Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cornerstone Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
6,857 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Commerzbank Aktiengesellschaft FI - MarketBeat
Deutsche Bank AG Invests $784.39 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
BlackRock Inc. Invests $11.98 Billion in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):